3.1 A medicine must not be promoted prior to the grant of the marketing authorization which permits its sale or supply.
Back to top Supplementary information
3.2 The promotion of a medicine must be in accordance with the terms of its marketing authorization and must not be inconsistent with the particulars listed in its summary of product characteristics.
Back to top
Clause 3 Marketing Authorization
The legitimate exchange of medical and scientific information during the development of a medicine is not prohibited provided that any such information or activity does not constitute promotion which is prohibited under this or any other clause.
Clause 3 Promotion at International Meetings
The promotion of medicines at international meetings held in the UK may on occasion pose certain problems with regard to medicines or indications for medicines which do not have a marketing authorization in the UK although they are so authorized in another major industrialised country. The display and provision of promotional material for such medicines is permitted at international meetings in the UK provided that the following conditions are met:
Clause 3.1 Advance Notification of New Products or Product Changes which May Significantly Affect Expenditure
NHS organisations and others involved in the purchase of medicines need to estimate their likely budgets in advance and there is a need for them to receive advance information about the introduction of new medicines, or changes to existing medicines, which may significantly affect their level of expenditure. At the time this information is required, the medicines concerned (or the changes to them) will not be the subject of marketing authorizations (though applications will often have been made) and it would be in breach of the Code for them to be promoted. Companies wishing to provide advance notification must ensure that information is also provided wherever possible for inclusion in national horizon scanning databases. Non-promotional information can be provided as advance notification but it must:
i) relate to:
(a) a product which contains a new active substance, or (b) a product which contains an active substance prepared in a new way, such as by the use of biotechnology, or(c) a product which is to have a significant addition to the existing range of authorized indications, or (d) a product which is to have a novel and innovative means of administration
ii) only be directed to those responsible for making policy decisions on budgets and not those expected to prescribe iii) state whether or not a new medicine or a change to an existing medicine is the subject of a marketing authorization in the UK iv) state the likely cost or savings and budgetary implications which must be such that they will significantly change the organisation’s likely expenditure v) be factual and limited to that sufficient to provide an adequate but succinct account of the product’s properties; other products should only be mentioned to put the new product into context in the therapeutic area concerned The information provided must not: i) be promotional in style – product logos should be avoided but company logos may be used; the brand name of the product may be included in moderation but it should not be stylised or used to excess ii) include mock up drafts of either summaries of product characteristics or package leaflets. If requested further information may be supplied or a presentation made.
Back to top
Back to clause
Clause 3.2 Unauthorized Indications
The promotion of indications not covered by the marketing authorization for a medicine is prohibited by this clause.
Back to top
Back to clause